Lenzilumab is variant agnostic so its efficacy will not be affected by mutations. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency https://www.nature.com/articles/s41423-021-00779-5